Avastin

AVASTIN® (bevacizumab) Label

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AVASTIN safely and effectively. See full prescribing information for AVASTIN.

www.accessdata.fda.gov

C IGNA M EDICAL C OVERAGE P OLICY - Bevacizumab (Avastin

FDA Approved Indications NOTE: Effective 12/16/2010 The Food and Drug Administration (FDA) announced that the agency is recommending removing the breast cancer indication from the label for Avastin (bevacizumab) because the

www.cigna.com

• Do not initiate Avastin for 28 days following major ...

U.S. BL 125085 Supplement: Bevacizumab ! Genentech, Inc. 1 of 23 /Regional: Avastin_Master Word_Approved_21 December 2011.docx HIGHL IGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AVASTIN safely and effectively .

www.gene.com

HIGHLIGHTS OF PRESCRIBING INFORMATION

U.S. BL 125085 Supplement: Bevacizumab ⎯ Genentech, Inc. 1 of 25/Regional (PAS) (Labeling): Final Draft PI HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AVASTIN safely and effectively.

www.accessdata.fda.gov

Avastin* in breast cancer: Summary of clinical data

1 Avastin * in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading cause of cancer death in women 1.

www.roche.com

Avastin (Bevacizumab) Intravitreal Injection

into your eye as needed at regular intervals (about every six to twelve weeks); your ophthalmologist will tell you how often you will receive the injection, and for how long.

www.eyehospital.com.au

Drug Therapy Guidelines: Avastin® (Bevacizumab)

Drug Therapy Guidelines: Avastin® (Bevacizumab) Effective Date: 11/20/07 Committee Review Date: 10/15/06, 11/5/07 Policy Statements: Non-Formulary or Prior Authorization drugs will require an appropriate trial of a Formulary agent(s) based on clinical criteria.

www.bcbswny.com

Cigna Medical Coverage Policy

FDA Approved Indications NOTE: On June 29, 2011, the FDA’s Oncologic Drugs Advisory Committee recommended withdrawing approval of bevacizumab (Avastin) for breast cancer.

www.cigna.com

AVASTIN™ (BEVACIZUMAB) INTRAVITREAL INJECTION

AVASTIN ™ (BEVACIZUMAB) INTRAVITREAL INJECTION INDICATIONS Age-related macular degeneration (AMD) is the leading cause of blindness in people over 50 years of age.

www.retinaconsultantsnj.com

IMPORTANT PRESCRIBING INFORMATION

fda commissioner revokes approval of avastin for treatment of her2-negative metastatic breast cancer (mbc) in the united states

www.gene.com

Other sites you could try:

Find videos related to Avastin